This is an antibacterial drug-mechanism module, not a specific disease. Disorder entries reference individual nodes via conforms_to (e.g., "bacterial_cell_wall_synthesis_inhibition#Peptidoglycan Cross-Linking by Penicillin-Binding Proteins"), and their cell-wall-active treatments point at the inhibited node via target_mechanisms (analogous to how checkpoint inhibitor treatments link to "immune_checkpoint_blockade#Adaptive Immune Resistance"). Key conformance / treatment target: "Peptidoglycan Cross-Linking by Penicillin-Binding Proteins" (the beta-lactam target). The module is pathogen-process-centric: nodes are druggable steps in the conserved pathway, not individual drugs; a given antibiotic class maps to the step it inhibits. The two resistance nodes capture the gating knowledge that distinguishes "any cell-wall agent works" from real drug selection — intrinsic target absence in cell-wall-deficient organisms, and acquired protection of the pathway.
Peptidoglycan Precursor and Lipid II Synthesis
trigger
Cytoplasmic enzymes (MurA-MurF, Alr/Ddl) assemble the UDP-MurNAc-pentapeptide precursor terminating in a D-Ala-D-Ala dipeptide, which is transferred to the membrane lipid carrier to form lipid I and then lipid II — the universal substrate exported across the membrane for polymerization. Several antibiotic classes act here rather than at the final cross-linking step: fosfomycin inhibits the first committed enzyme MurA, D-cycloserine blocks D-Ala racemase and ligase, bacitracin blocks recycling of the lipid carrier, and glycopeptides (vancomycin, teicoplanin) bind and sequester the exposed D-Ala-D-Ala terminus of lipid II. Because glycopeptides recognize the substrate rather than an enzyme, their target can be remodeled to D-Ala-D-Lac in resistant enterococci and staphylococci.
Used by disorders
Endophthalmitis
as Bacterial Peptidoglycan Precursor and Lipid II Synthesis (Vancomycin Target)
Downstream
-
Peptidoglycan Cross-Linking by Penicillin-Binding Proteins
Polymerized glycan strands assembled from lipid II are cross-linked by PBP transpeptidases to form the mature sacculus.
Show evidence (1 reference)
"the antimicrobial activity of other vancosamine-modified glycopeptides depends upon both d-Ala-d-Ala stem-terminus recognition (primary binding site) and stem-bridge recognition (secondary binding site)."
Solid-state NMR study confirming that glycopeptide antibiotics act by recognizing the D-Ala-D-Ala stem terminus of the peptidoglycan precursor, supporting this lipid II / precursor step as the glycopeptide drug target. Evidence source is IN_VITRO as this is a biochemical study of isolated cell walls.
Peptidoglycan Cross-Linking by Penicillin-Binding Proteins
therapeutic vulnerability
Glycosyltransferases polymerize the glycan backbone while DD-transpeptidases, also called penicillin-binding proteins (PBPs), cross-link the peptide stems to give peptidoglycan its load-bearing, mesh-like strength. This transpeptidation reaction is the target of beta-lactam antibiotics (penicillins, cephalosporins, carbapenems, monobactams), which are structural analogues of the D-Ala-D-Ala terminus and covalently acylate the PBP transpeptidase active-site serine, irreversibly inactivating it. This is the central, most widely exploited node of the module and the canonical conformance / treatment target for cell-wall-active therapy. Loss of cross-linking weakens the wall during active growth, which is why beta-lactams are most effective against dividing bacteria.
Used by disorders
Actinomycosis
as Actinomyces Peptidoglycan Cross-Linking (Beta-Lactam Target)
Bejel
as Treponemal Peptidoglycan Cross-Linking (Beta-Lactam Target)
Chancroid
as H. ducreyi Peptidoglycan Cross-Linking (Ceftriaxone Target)
Diphtheria
as Bacterial Peptidoglycan Cross-Linking (Beta-Lactam Target)
Endophthalmitis
as Bacterial Peptidoglycan Cross-Linking by Penicillin-Binding Proteins (Beta-Lactam Target)
Furunculosis
as Staphylococcal Peptidoglycan Cross-Linking (Beta-Lactam Target)
Gonorrhea
as Gonococcal Penicillin-Binding Protein Cross-Linking (Ceftriaxone Target)
Leptospirosis
as Leptospiral Peptidoglycan Cross-Linking (Beta-Lactam Target)
Ludwig's Angina
as Oral Flora Peptidoglycan Cross-Linking (Beta-Lactam Target)
Lyme Disease
as Borrelial Peptidoglycan Cross-Linking (Beta-Lactam Target)
Melioidosis
as B. pseudomallei Peptidoglycan Cross-Linking (Beta-Lactam Target)
Pinta
as Treponemal Peptidoglycan Cross-Linking (Beta-Lactam Target)
Scarlet Fever
as Streptococcal Peptidoglycan Cross-Linking (Beta-Lactam Target)
Syphilis
as Treponemal Peptidoglycan Cross-Linking (Beta-Lactam Target)
Whipple Disease
as Tropheryma Peptidoglycan Cross-Linking (Beta-Lactam Target)
Downstream
-
Cell Envelope Integrity Failure and Bactericidal Autolysis
When cross-linking is pharmacologically inhibited, the unbalanced action of peptidoglycan hydrolases ruptures the sacculus.
-
Acquired Resistance and Drug Inactivation
Bacteria can protect this step from inhibition by destroying the drug or altering the target enzyme, escaping cell-wall-active therapy.
Show evidence (3 references)
"Peptidoglycan synthesis requires glycosyltransferases (GTases) to polymerize the glycan chains and DD-transpeptidases (DD-TPases) to crosslink the peptides"
Review establishing that cross-linking of peptide stems by DD-transpeptidases (PBPs) is a required step of peptidoglycan synthesis. Evidence source is OTHER as this is a review article.
"although glycan chain polymerization occurs in the absence of transpeptidation (for example, in the presence of penicillin), efficient transpeptidation requires ongoing GTase reactions"
Directly states that penicillin abolishes transpeptidation (the PBP cross-linking reaction), confirming this node as the beta-lactam target. Evidence source is OTHER as this is a review article.
"This review focuses on the detailed structure of PBPs and their implication in peptidoglycan synthesis, maturation and recycling."
Dedicated review of penicillin-binding proteins and their role in peptidoglycan biosynthesis, the enzymatic step inhibited by beta-lactams. Evidence source is OTHER as this is a review article.
Cell Envelope Integrity Failure and Bactericidal Autolysis
consequence
Peptidoglycan is the load-bearing layer that resists internal turgor pressure. When its synthesis is inhibited, the bacterium's own peptidoglycan hydrolases (autolysins) continue to cleave bonds in the sacculus without balanced resynthesis, leading to uncontrolled hydrolysis, rupture of the cell envelope, and lysis. Because this depends on active wall turnover, cell-wall inhibitors are bactericidal against growing cells and relatively inactive against dormant/stationary-phase organisms. The selectivity of this outcome — bacteria have peptidoglycan and human cells do not — underlies the high therapeutic index of beta-lactams and glycopeptides.
Show evidence (1 reference)
"On inhibition of peptidoglycan synthesis, uncontrolled hydrolase activity results in rupture of the sacculus and cell lysis"
Directly states the bactericidal mechanism of cell-wall-active drugs: inhibiting peptidoglycan synthesis lets autolysins rupture the sacculus, causing lysis. Evidence source is OTHER as this is a review article.
Acquired Resistance and Drug Inactivation
adaptive escape
Bacteria acquire resistance to cell-wall-active agents by three principal routes that map onto the steps above: enzymatic inactivation of the drug (beta-lactamases hydrolyze the beta-lactam ring before it reaches the PBP), modification or protection of the target enzyme (acquisition of a low-affinity PBP such as staphylococcal PBP2a, conferring methicillin resistance), and remodeling of the drug-binding substrate (replacement of the lipid II D-Ala-D-Ala terminus with D-Ala-D-Lac in vancomycin-resistant enterococci, abolishing glycopeptide binding). This node explains why a nominally "cell-wall-active" antibiotic can fail against a specific organism and why agent selection — narrow-spectrum penicillin vs beta-lactamase-stable cephalosporin/carbapenem vs anti-MRSA agent — is mechanism-driven.
Used by disorders
Furunculosis
as Methicillin Resistance via Low-Affinity PBP2a (MRSA)
Gonorrhea
as penA Mosaic Alleles and Cephalosporin Resistance
Show evidence (1 reference)
"the mechanisms by which bacteria are either intrinsically resistant or acquire resistance to antibiotics, including the prevention of access to drug targets, changes in the structure and protection of antibiotic targets and the direct modification or inactivation of antibiotics."
Review enumerating the resistance mechanisms encoded here — target protection/alteration (e.g. PBP2a) and direct drug inactivation (e.g. beta-lactamase). Evidence source is OTHER as this is a review article.
Intrinsic Resistance in Cell-Wall-Deficient Organisms
intrinsic resistance
This module's entire mechanism presupposes a peptidoglycan target. Organisms of the class Mollicutes (Mycoplasma, Ureaplasma) lack a cell wall entirely, so beta-lactams, glycopeptides, and fosfomycin have no target and are intrinsically inactive regardless of dose. This is the clearest example of mechanism gating drug choice: such infections must be treated with agents acting on other targets (macrolides, tetracyclines, fluoroquinolones). Disorder entries for cell-wall-deficient pathogens should NOT declare conforms_to against the cross-linking node; this node documents the negative case and the reason cell-wall-active therapy is excluded.
Show evidence (1 reference)
"antimicrobial treatment options are limited, partly due to the lack of a cell wall in these peculiar bacteria."
Review of mycoplasma antimicrobial resistance stating that the absence of a cell wall limits treatment options — i.e. removes the target of cell-wall-active antibiotics. Evidence source is OTHER as this is a review article.